Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Risk for Anal Cancer Elevated Among Women With History of Cervical Cancer
TUESDAY, Sept. 16, 2025 -- The overall standardized incidence ratio for anal cancer is elevated among women with a history of cervical cancer, according to a...
Half Discontinue Semaglutide for Weight Loss Within One Year
TUESDAY, Sept. 16, 2025 -- Half of adults who start semaglutide for weight loss discontinue within a year, according to a study presented at the annual...
Nicotine Pouch Use May Be a Harm Reduction Strategy
TUESDAY, Sept. 16, 2025 -- The percentage of U.S. adults using nicotine pouches remains low, according to a research letter published online Sept. 8 in JAMA...
Women Still Underrepresented in Cardiovascular Trials
TUESDAY, Sept. 16, 2025 -- In recent years, challenges have persisted in representation of women within cardiovascular (CV) clinical trials, according to a...
Parent-Focused Interventions Do Not Prevent Obesity at Age 24 Months
TUESDAY, Sept. 16, 2025 -- Parent-focused behavioral interventions seem to be insufficient for preventing obesity at age 24 months, according to a review...
U.S. Officials To Review COVID Vaccine Safety in Pregnancy, Kids
TUESDAY, Sept. 16, 2025 — Federal health officials are reviewing safety data on COVID vaccines in pregnant women and children, and may also reconsider r...
Goodles Mac & Cheese Recalled Due to Hidden Allergen Risk
TUESDAY, Sept. 16, 2025 — Gooder Foods, Inc. is recalling eight lots of its boxed mac and cheese products because they may contain undeclared allergens, f...
RFK Jr. Adds 5 Members to Vaccine Advisory Committee Ahead of Meeting
TUESDAY, Sept. 16, 2025 — Five new members have been appointed to the U.S. Centers for Disease Control and Prevention’s (CDC) vaccine advisory committee, fed...
Over 100,000 Paris Hilton Mini Fridges Recalled for Fire Risk
TUESDAY, Sept. 16, 2025 — More than 100,000 Paris Hilton-branded mini fridges are being recalled because of a risk of fire and burns, federal safety officials...
Over-The-Counter Sales Of OD-Reversal Drug Have Been A Bust
TUESDAY, Sept. 16, 2025 — Over-the-counter sales have tanked for the overdose reversal drug naloxone, likely due to its high price, a new study says.Naloxone (...
FDA Approves Enbumyst (bumetanide) Nasal Spray for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease
HENDERSON, Nev.--(BUSINESS WIRE) September 15, 2025 --Corstasis Therapeutics Inc., an innovative biopharmaceutical company providing enhanced outpatient...
Intercept Announces Voluntary Withdrawal of Ocaliva for Primary Biliary Cholangitis (PBC) from the US Market; FDA Places US Clinical Trials on Hold
September 12, 2025. MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of...
FDA Approves Selumetinib for Pediatric Patients 1 year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas
On September 10, 2025, the Food and Drug Administration approved selumetinib (Koselugo, AstraZeneca Pharmaceuticals LP) granules and capsules for pediatric...
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sep. 10, 2025-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery...
FDA Approves Inlexzo (gemcitabine intravesical system) for the Treatment of Non-Muscle Invasive Bladder Cancer
September 9, 2025. RARITAN, N.J., September 9, 2025 /PRNewswire/ – Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration...
U.S. FDA Approves Expanded Indication for Vonvendi [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
OSAKA, Japan and CAMBRIDGE, Massachusetts, September 5, 2025 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration...
Stealth Biotherapeutics Announces FDA Acceptance of Elamipretide NDA Resubmission
NEEDHAM, Mass., Aug. 21, 2025 /PRNewswire/ — Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and...
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
WARREN, N.J., Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a...
Stealth Biotherapeutics Resubmits New Drug Application for Elamipretide for the Treatment of Barth Syndrome
NEEDHAM, Mass., Aug. 18, 2025 /PRNewswire/ — Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development...
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
NEW HAVEN, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today with its partner Pfizer Inc. (NYSE: PFE), announced that the U.S. Food...
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company...
Baxdrostat Demonstrated Statistically Significant and Clinically Meaningful Reduction in Systolic Blood Pressure in Patients with Hard-to-Control Hypertension in the BaxHTN Phase III Trial
30 August 2025 -- Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful r...
Regeneron Announces Positive Results from Phase 3 Trial of Cemdisiran in Generalized Myasthenia Gravis
TARRYTOWN, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary and key secondary endpoints...
Lilly's Oral GLP-1, Orforglipron, is Successful in Third Phase 3 Trial, Triggering Global Regulatory Submissions This Year for the Treatment of Obesity
INDIANAPOLIS, Aug. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-2 trial...
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
NEWARK, CA / ACCESS Newswire / August 25, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or "the Company") announced today that rusfertide, a potential...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
Drugs.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.